MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer. - German B; Singh JN; Fonseca MA; Burkhart DL; Sheahan A; Bergom H; Morel KL; Beltran H; Hwang JH; Lawrenson K; Ellis L (BioRxiv : the preprint server for biology, 2024)